



University of Dundee

The association of age at menarche and adult height with mammographic density in the International Consortium of Mammographic Density

Ward, Sarah V.; Burton, Anya; Tamimi, Rulla M.; Pereira, Ana; Garmendia, Maria Luisa; Pollan, Marina

Published in: **Breast Cancer Research**

DOI: 10.1186/s13058-022-01545-9

Publication date: 2022

Licence: CC BY

Document Version Publisher's PDF, also known as Version of record

Link to publication in Discovery Research Portal

Citation for published version (APA):

Ward, S. V., Burton, A., Tamimi, R. M., Pereira, A., Garmendia, M. L., Pollan, M., Boyd, N., Dos-Santos-Silva, I., Maskarinec, G., Perez-Gomez, B., Vachon, C., Miao, H., Lajous, M., López-Ridaura, R., Bertrand, K., Kwong, A., Ursin, G., Lee, E., Ma, H., ... Stone, J. (2022). The association of age at menarche and adult height with mammographic density in the International Consortium of Mammographic Density. Breast Cancer Research, 24, [49]. https://doi.org/10.1186/s13058-022-01545-9

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.

You may not further distribute the material or use it for any profit-making activity or commercial gain.
You may freely distribute the URL identifying the publication in the public portal.

Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

RESEARCH



The association of age at menarche and adult height with mammographic density in the International Consortium of Mammographic Density



Sarah V. Ward¹, Anya Burton^{2,3}, Rulla M. Tamimi⁴, Ana Pereira⁵, Maria Luisa Garmendia⁵, Marina Pollan^{6,7}, Norman Boyd⁸, Isabel dos-Santos-Silva⁹, Gertraud Maskarinec¹⁰, Beatriz Perez-Gomez^{6,7}, Celine Vachon¹¹, Hui Miao¹², Martín Lajous¹³, Ruy López-Ridaura¹³, Kimberly Bertrand¹⁴, Ava Kwong^{15,16,17}, Giske Ursin^{18,19,20}, Eunjung Lee²¹, Huiyan Ma²², Sarah Vinnicombe²³, Sue Moss²⁴, Steve Allen²⁵, Rose Ndumia²⁶, Sudhir Vinayak²⁶, Soo-Hwang Teo^{27,28}, Shivaani Mariapun²⁸, Beata Peplonska²⁹, Agnieszka Bukowska-Damska³⁰, Chisato Nagata³¹, John Hopper³², Graham Giles^{32,33}, Vahit Ozmen³⁴, Mustafa Erkin Aribal³⁵, Joachim Schüz¹, Carla H. Van Gils³⁶, Johanna O. P. Wanders³⁶, Reza Sirous³⁷, Mehri Sirous³⁸, John Hipwell³⁹, Jisun Kim⁴⁰, Jong Won Lee⁴⁰, Caroline Dickens⁴¹, Mikael Hartman^{12,42}, Kee-Seng Chia⁴³, Christopher Scott¹¹, Anna M. Chiarelli⁴⁴, Linda Linton⁸, Anath Arzee Flugelman⁴⁵, Dorria Salem⁴⁶, Rasha Kamal⁴⁶, Valerie McCormack^{2*} and Jennifer Stone¹

Abstract

Background: Early age at menarche and tall stature are associated with increased breast cancer risk. We examined whether these associations were also positively associated with mammographic density, a strong marker of breast cancer risk.

Methods: Participants were 10,681 breast-cancer-free women from 22 countries in the International Consortium of Mammographic Density, each with centrally assessed mammographic density and a common set of epidemiologic data. Study periods for the 27 studies ranged from 1987 to 2014. Multi-level linear regression models estimated changes in square-root per cent density (\sqrt{PD}) and dense area (\sqrt{DA}) associated with age at menarche and adult height in pooled analyses and population-specific meta-analyses. Models were adjusted for age at mammogram, body mass index, menopausal status, hormone therapy use, mammography view and type, mammographic density assessor, parity and height/age at menarche.

Results: In pooled analyses, later age at menarche was associated with higher per cent density ($\beta_{\sqrt{PD}} = 0.023$ SE = 0.008, P = 0.003) and larger dense area ($\beta_{\sqrt{DA}} = 0.032$ SE = 0.010, P = 0.002). Taller women had larger dense area ($\beta_{\sqrt{DA}} = 0.069$ SE = 0.028, P = 0.012) and higher per cent density ($\beta_{\sqrt{PD}} = 0.044$, SE = 0.023, P = 0.054), although the

*Correspondence: McCormackV@iarc.fr

² Environment and Lifestyle Epidemiology Branch, International Agency for Research on Cancer, 150 Cours Albert Thomas, 69372 Lyon Cedex 08, Fra nce

Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

observed effect on per cent density depended upon the adjustment used for body size. Similar overall effect estimates were observed in meta-analyses across population groups.

Conclusions: In one of the largest international studies to date, later age at menarche was positively associated with mammographic density. This is in contrast to its association with breast cancer risk, providing little evidence of mediation. Increased height was also positively associated with mammographic density, particularly dense area. These results suggest a complex relationship between growth and development, mammographic density and breast cancer risk. Future studies should evaluate the potential mediation of the breast cancer effects of taller stature through absolute breast density.

Keywords: Mammographic density, Menarche, Height, Breast cancer

Background

Several measures of growth and development across a woman's life course are associated with breast cancer risk. In particular, early age at menarche and tall stature have been associated with increased breast cancer risk [1, 2], pointing to an important exposure window in early childhood and adolescence. These associations may be mediated systemically through the insulin-like growth factor (IGF) or sex steroid pathways and thereby impact on the breast parenchyma [3]. Mammographic breast density is the white radiographic appearance of epithelial and stromal tissue on a mammogram and women with increased mammographic density (MD) for their age and body mass index (BMI) are at significantly higher risk for breast cancer [4, 5]. Breast cancer and MD share common predictors, such as parity and use of hormone therapy, suggesting that the effect of these factors on breast cancer risk may be mediated, at least partly, through MD [6]. Age and BMI, a measure of weight for body size (weight/height² in kilograms/metres² [kg/m²]), are exceptions to this consistency and negatively confound the association between MD and breast cancer risk [7, 8]. That is, the true risk factor is MD adjusted for a woman's age and BMI. There is also consistent evidence of an inverse association between pubertal body adiposity and adult MD [9-11]. Further, there is growing evidence that MD could mediate the inverse association of childhood BMI with breast cancer risk in pre-menopausal women [9, 12]. However, the associations of age at menarche and adult height, both of which are known breast cancer risk factors, with MD are less consistent and not well understood.

A recent review of pubertal mammary gland development as a determinant of adult MD summarizes the inconsistent reports of the association between age at menarche and MD. Half of the studies showed a positive association, and the other half showed either a negative or null association with MD [11]. The review also highlights the importance of adjustment for anthropometric measures when evaluating associations between age at menarche and MD, as increased body adiposity is associated with earlier pubertal development; hence, the association between age at menarche and MD is potentially dependent on childhood weight [11]. Similarly, inconsistent results have also been observed between MD and height. MD in adult women has been positively associated with both adult height [13, 14] and childhood height [15] in some studies, whilst no association has been observed in other studies [9, 16].

In the present study, we therefore examined associations of age at menarche and adult height with two measures of MD, per cent density (PD) and dense area (DA), in the International Consortium of Mammographic Density (ICMD). This international study pools data from 11,755 women from 22 countries spanning all continents worldwide, with centrally measured MD and a common core set of epidemiologic data. An important consideration when investigating the independent effects of any outcome on MD in an international study is the influence of population groups and ethnicity on observed associations. For example, age at menarche and adult stature tend to be positively correlated within populations, because an early menarche is followed by an earlier timing of the maximal height velocity and thus final adult height is shorter [17, 18]. Across populations, however, these correlation structures may differ if growth and development are associated with decreasing age at menarche and with increasing adult height [17]. These factors are taken into consideration in the present study. The diversity of ethnicities and of growth and development patterns in the ICMD enhances exposure heterogeneity and allows examination of the consistency of associations across populations.

Methods

Study design and participants

We examined two markers of developmental growth, age at menarche and adult height, in relation to measures of MD in the ICMD. The ICMD methodology and contributing studies are discussed in detail elsewhere [19]. Briefly, the consortium pooled individual-level data from studies investigating MD and its putative determinants in breast cancer-free women, purposefully including studies from diverse countries and ethnic groups with different underlying breast cancer incidence rates. In total, 11,755 women were included from 27 studies in 22 countries, forming 40 location and ethnicity-specific 'population groups' (Figs. 1, 2, 3, 4). Population groups included the broad ethnic groups of Black, East Asian, South Asian, Hawaiian, Mestizo, Middle Eastern and White women (see Table 1 for breakdown by country). In each population group, there were approximately 200 pre- and 200 post-menopausal women aged 35 years or older at the time of mammography. Mammograms were originally taken as part of organized screening (n=13 studies), opportunistic or community-based screening (n=8), mammography trials (n=3) or for research (n=3).

In the current study, further exclusions were made from the total 11,755 women. First, women from very small ethnic groups within each study were excluded (n=129 across four countries), then women with no MD information due to poor image quality (n=529), inconsistent age at first birth compared to age at menarche (n=5) and 'nulliparous' women who had children (n=6), implausible/missing BMI (n=2), missing parity (n=93)and missing age at menarche (n=310). This resulted in a total of 10,681 women for analyses.

Exposures of interest and confounders/modifiers

Individual-level data on sociodemographic and lifestyles factors were harmonized across all ICMD studies. Age at menarche data was self-reported in adulthood and collected as integers or categories, with the median values of each category assumed for continuous analyses. Categorical analyses were performed using previously used cut-points (<12, 12 to <13, 13 to <14, 14 to <15, and 15 years and older). Height was recorded in centimetres (cm) in the majority of studies and converted to centimetres for those recorded in feet and inches. Height was examined both as a continuous variable (per 10 cm increase) and as a categorical variable (<155, 155 to <160, 160 to <165, \geq 165 cm).

Weight was recorded in kilograms for most studies and converted from stones and pounds for all other studies. A measure of BMI was calculated for all participants as kg/m². Information on the method of height and weight ascertainment was also collected, either as self-reported (n=3370, 32%) or measured (n=7061, 66%) and was not known in one study (n=249, 2%).

Other variables included in the present analyses included age at mammogram, parity, age at first birth, and use of hormone therapy at the time of mammography. Study-specific definitions were used and then harmonized for menopausal status, as has been described in detail previously [20].

Mammographic density measurement

In the ICMD, MD was measured centrally from digitized film mammograms and raw or processed digital images by one of three experienced assessors (authors VM, IdSS, NB) using the software program Cumulus [21]. For each woman, one mammographic image (cranio-caudal or medio-lateral oblique view) was measured. To assess the intra- and inter-assessor reliability, approximately 20% of the images were re-measured, providing repeated measures for a subset of women, as detailed previously [19]. This resulted in a total of 12,586 MD measurements for the 10,681 women in present analyses. The MD measures used in these analyses were DA (cm²) and PD $(PD = 100 \times DA/breast area)$, as they were considered the most aetiologically relevant. The measures from processed images were corrected to a raw image equivalent using published equations [22].

Statistical methods

Descriptive analyses were conducted in the broad ethnic groups of Black, East Asian, South Asian, Hawaiian, Mestizo, Middle Eastern and White women to summarise the data. Two analytical approaches were then taken to examine the associations between age at menarche and adult height with the outcomes PD and DA. Both of these approaches used the more specific population groups to take into account ethnic differences between participants. Both MD outcomes were first square-roottransformed to normalize residuals. PD and DA are both area measures, so if they are considered as squares, this transformation implies that regression beta-coefficients can be interpreted as the effect on the length of the side of a square, e.g. if DA = 25 cm, $\sqrt{DA} = 5$ cm (a square of 5×5 cm), and beta = +0.1 cm, then the length of the DA square increases from 5.0 to 5.1 cm, and the corresponding DA increases from 25 to $5.1^2 = 26.0$ cm [20].

In the first analytical approach, population-specific associations were examined and their effect estimates combined using meta-analytic approaches with a random effects model. Forest plots were used to display population-specific effect estimates. Second, individuallevel pooled analyses were performed using multi-level models with density measures clustered for an individual, who was clustered within their population group. Individual-level clustering was used to account for women with repeated measures, and population group clustering to account for differences in ethnicity between groups.

In both approaches, all models were adjusted for age at mammogram (cubed due to best fit), menopausal status, use of hormone therapy, mammogram view, calibration method, mammogram reader, parity and BMI (quadratic or cubed terms depending on best fit). To evaluate the

Study	Change in square-root PD (95% CI)	No. women
US-USC-Asian	-0.08 (-0.24, 0.07)	59
US-USC-White	-0.06 (-0.19, 0.07)	178
UK-London-White	-0.05 (-0.16, 0.05)	279
Singapore-Malay	-0.05 (-0.12, 0.02)	235
Israel-Arab	-0.04 (-0.18, 0.10)	291
Egypt	-0.03 (-0.10, 0.04)	562
Singapore-Indian	-0.02 (-0.09, 0.05)	247
Norway	-0.02 (-0.14, 0.10)	242
Australia-Australian	-0.02 (-0.11, 0.07)	447
Australia-Greek	-0.02 (-0.16, 0.12)	160
US-NHS-White	-0.01 (-0.10, 0.08)	485
Iran —	-0.01 (-0.06, 0.05)	461
Netherlands	-0.00 (-0.08, 0.08)	418
Mexico	0.00 (-0.08, 0.09)	159
Singapore-Chinese	0.00 (-0.08, 0.09)	213
Spain —	0.00 (-0.05, 0.06)	893
Kenya	0.01 (-0.07, 0.08)	268
US-MEC-White	0.01 (-0.13, 0.15)	181
Korea	0.01 (-0.06, 0.08)	448
UK-Eth Black	0.02 (-0.08, 0.12)	253
UK-Eth-White	0.02 (-0.09, 0.13)	281
Malaysia-Indian	0.03 (-0.09, 0.14)	288
UK-Eth-South Asian	• 0.03 (-0.09, 0.15)	117
Turkey	♦ 0.03 (-0.06, 0.12)	452
Canada	0.04 (-0.07, 0.15)	377
US-Mayo-White	0.04 (-0.06, 0.14)	458
Malaysia-Chinese	• 0.04 (-0.04, 0.12)	467
South Africa	• 0.04 (-0.02, 0.10)	423
Poland	0.05 (-0.03, 0.13)	492
Hong Kong —	0.06 (-0.04, 0.15)	226
Malaysia-Malay —	0.06 (-0.06, 0.18)	270
UK-Age Trial-White	0.07 (-0.08, 0.21)	197
Israel-Jewish	• 0.07 (-0.06, 0.20)	332
Chile	0.07 (-0.03, 0.17)	274
US-MEC-Hawaiian	0.08 (-0.06, 0.21)	158
Japan	0.09 (0.00, 0.17)	454
US-USC-Black	0.09 (-0.03, 0.21)	129
US-MEC-Japanese	0.16 (0.07, 0.24)	293
Australia-Italian	0.19 (0.07, 0.30)	211
Overall (I-squared = 12.1%, p = 0.258)	0.02 (0.00, 0.03)	
Random effects analysis		
	· · · · · ·	<u> </u>

Fig. 1 Association of age at menarche (per year) with per cent density. Forest plot depicting results from a meta-analysis of the association of age at menarche (per year) with square-root per cent density of the breast, in studies from the International Consortium on Mammographic Density. Effect estimates for each separate population group are shown, as well as the combined effect estimate, from random effects model

US-USC-White -0.10 (0.30, 0.11) 178 US-USC-Asian -0.08 (0.34, 0.17) 59 Australia-Australian -0.08 (0.19, 0.00) 447 UK-London-White -0.07 (0.21, 0.06) 279 Australia-Greek -0.06 (0.19, 0.07) 485 US-NHS-White -0.06 (0.19, 0.07) 485 Israel-Arab -0.06 (0.16, 0.07) 562 Kenya -0.04 (0.15, 0.07) 562 Kenya -0.02 (0.11, 0.07) 562 Singapore-Malay -0.02 (0.11, 0.07) 225 UK-Eth Elack -0.02 (0.10, 0.07) 247 US-Mayo-White -0.00 (0.13, 0.12) 458 UK-Eth Elack -0.00 (-0.14, 0.15) 281 Iran 0.00 (-0.07, 0.08) 893 Turkey 0.01 (-0.13, 0.12) 458 UK-Eth-South Asian 0.02 (-0.14, 0.15) 452 UK-Eth-South Asian 0.02 (-0.14, 0.17) 452	Study	Change in square-root dense area (95% Cl).	No. women
US-USC-Asian Australia-Australian UK-London-White UK-London-White US-NHS-White US-NHS-White US-NHS-White US-NHS-White US-NHS-White US-NHS-White US-NHS-White US-NHS-White UK-Em Black Singapore-Malay UK-Em Black UK-Eth-White UK-Eth-White UK-Eth-White UK-Eth-White UK-Eth-South Asian UK-Eth-South Asian UK-EC-White UK-MEC-Hawaiian UK-MEC-HAWAIIA UK-MEC-HAWAIIA U	US-USC-White	-0.10 (-0.30, 0.11)	178
Australia-Australian -0.08 (0.19, 0.04) 447 UK-London-White -0.07 (0.21, 0.06) 279 Australia-Australian -0.08 (0.19, 0.07) 445 Israel-Arab -0.08 (0.19, 0.07) 445 Israel-Arab -0.08 (0.19, 0.07) 445 Israel-Arab -0.06 (0.26, 0.16) 291 Egypt -0.04 (0.15, 0.07) 562 Kerya -0.04 (0.15, 0.07) 562 Netherlands -0.03 (0.12, 0.07) 418 Singapore-Indian -0.02 (0.11, 0.07) 225 UK-Eth Black -0.02 (0.11, 0.07) 245 UK-Eth-White -0.00 (0.13, 0.12) 458 UK-Eth-White -0.00 (0.13, 0.15) 452 UK-Eth-White -0.00 (0.13, 0.15) 452 UK-Eth-White -0.00 (0.01, 0.01) 471 Iran 0.00 (0.08, 0.09) 461 Spain 0.00 (0.07, 0.08 833 Turkey 0.01 (0.13, 0.15) 452 UK-Eth-White 0.03 (0.12, 0.18) 242 US-MEC-White 0.03 (0.14, 0.20) 181 South Africa 0.04 (0.0		-0.08 (-0.34, 0.17)	59
Uk-London-White -0.05 (0.21, 0.06) 279 Australia-Greek -0.07 (0.21, 0.06) 279 Justralia-Greek -0.07 (0.26, 0.13) 160 US-NHS-White -0.06 (0.19, 0.07) 485 Israel-Arab -0.05 (0.26, 0.16) 291 Egypt -0.04 (0.15, 0.07) 562 Kenya -0.04 (0.15, 0.07) 268 Netherlands -0.02 (0.16, 0.13) 253 UK-Eth Black -0.02 (0.16, 0.13) 253 Singapore-Indian -0.02 (0.16, 0.13) 253 Singapore-Indian -0.02 (0.16, 0.13) 253 UK-Eth Black -0.02 (0.16, 0.13) 251 Iran 0.00 (0.04, 0.09) 461 Spain 0.00 (0.07, 0.08) 893 Turkey 0.01 (0.13, 0.15) 452 UK-Eth Haiayia-Malay 0.02 (0.14, 0.18) 270 Singapore-Chinese 0.02 (0.14, 0.18) 271 Norway 0.03 (0.12, 0.18) 242 US-MEC-Minie 0.04 (0.06, 0.17) 492 Korea 0.06 (0.02, 0.3) 444 Canada 0.06 (0.02, 0.3)		-0.08 (-0.19, 0.04)	447
On Constant All 0.03 (0.12, 0.07) 485 Australia-Greek 0.03 (0.12, 0.07) 485 Israel-Arab 0.03 (0.12, 0.07) 485 Egypt 0.04 (0.15, 0.07) 268 Netherlands 0.03 (0.12, 0.07) 418 Singapore-Malay 0.02 (0.11, 0.07) 285 UK-Eth Black -0.02 (0.11, 0.07) 247 US-Mayo-White -0.00 (0.13, 0.12) 458 UK-Eth Black -0.00 (0.01, 0.13) 253 Singapore-Indian -0.02 (0.11, 0.07) 247 US-Mayo-White -0.00 (0.01, 0.13) 253 UK-Eth Black -0.00 (0.01, 0.13) 253 Singapore-Indian -0.02 (0.11, 0.07) 247 US-Mayo-White -0.00 (0.07, 0.08) 893 Turkey 0.01 (0.01, 0.18) 242 UK-Eth-South Asian 0.02 (0.14, 0.17) 117 Malaysia-Malay 0.02 (0.14, 0.17) 121 Norway 0.03 (0.12, 0.18) 242 US-MEC-White 0.03 (0.12, 0.18) 242 US-MEC-Hamie 0.04 (0.06, 0.21) 443 Norway <t< td=""><td></td><td></td><td>279</td></t<>			279
US-NHS-White -0.06 (-0.19, 0.07) 485 Israel-Arab -0.05 (-0.28, 0.16) 291 Egypt -0.04 (-0.15, 0.07) 682 Kenya -0.04 (-0.15, 0.07) 688 Netherlands -0.03 (-0.12, 0.07) 148 Singapore-Malay -0.02 (-0.11, 0.07) 245 UK-Eh Black -0.02 (-0.11, 0.07) 247 US-Mayo-White -0.00 (-0.13, 0.12) 583 UK-Eh-White -0.00 (-0.13, 0.15) 545 UK-Eh-South Asian 0.02 (-0.14, 0.15) 117 Malaysia-Malay 0.02 (-0.14, 0.12) 123 Norway 0.03 (-0.12, 0.21) 181 South Africa 0.04 (-0.06, 0.14) 467 Poland 0.05 (-0.06, 0.17) 492 Korea 0.06 (-0.02, 0.23) 158 Japan 0.10 (-0.03, 0.23) 159 US-MEC-Hawaiian 0.10 (-0.03, 0.23) 159 US-MEC-Hawaiian 0.10	Australia-Greek	-0.07 (-0.26, 0.13)	160
Israel-Arab -0.05 (0.22, 0.103) 291 Egypt -0.04 (0.15, 0.07) 562 Kenya -0.04 (0.15, 0.07) 268 Netherlands -0.02 (0.11, 0.07) 235 UK-Eh Black -0.02 (0.11, 0.07) 247 US-Mayo-White -0.00 (0.13, 0.12) 458 UK-Eh Black -0.00 (0.13, 0.12) 458 UK-Eh Hack -0.00 (0.13, 0.12) 458 UK-Eh Hack -0.00 (0.00, 0.09) 461 Spain 0.00 (0.00, 0.09) 461 Spain 0.00 (0.00, 0.09) 461 Spain 0.00 (0.01, 0.15) 452 UK-Eh Havinte 0.00 (0.00, 0.09) 461 Spain 0.02 (0.14, 0.17) 117 Malaysia-Malay 0.02 (0.14, 0.18) 270 Singapore-Chinese 0.02 (0.04, 0.19) 242 US-MEC-White 0.03 (0.11, 0.20) 181 South Africa 0.04 (0.06, 0.11) 423 Malaysia-Indian 0.08 (0.00, 0.22) 377 Malaysia-Indian 0.08 (0.00, 0.22) 274 UK-Age Trial-White 0.11 (0.00, 0.23)	US-NHS-White	-0.06 (-0.19, 0.07)	485
Eayrt -0.04 (0.15, 0.07) 562 Kenya -0.03 (0.12, 0.07) 418 Singapore-Malay -0.02 (0.11, 0.07) 235 UK-Eth Black -0.02 (0.11, 0.07) 235 UK-Eth Black -0.00 (0.11, 0.07) 247 US-Mayo-White -0.00 (0.11, 0.07) 248 UK-Eth-White -0.00 (0.13, 0.12) 458 UK-Eth-White -0.00 (0.01, 0.15) 251 Turkey 0.01 (0.13, 0.15) 452 UK-Eth-South Asian 0.02 (0.14, 0.17) 117 Malaysia-Malay 0.02 (0.14, 0.17) 117 Malaysia-Malay 0.02 (0.14, 0.18) 270 Singapore-Chinese 0.02 (0.14, 0.12) 121 Norway 0.03 (0.12, 0.18) 242 US-MEC-White 0.03 (0.12, 0.18) 242 US-MEC-White 0.03 (0.14, 0.22) 181 South Africa 0.04 (-0.06, 0.17) 492 Korea 0.06 (-0.02, 0.13) 448 Canada 0.08 (-0.09, 0.22) 288 Japan 0.10 (-0.03, 0.23) 159 US-MEC-Havaiian 0.10 (-0.03, 0.23)<	Israel-Arab	-0.05 (-0.26, 0.16)	291
Kenya -0.04 (40.15, 0.07) 268 Netherlands -0.03 (40.12, 0.07) 418 Singapore-Malay -0.02 (40.11, 0.07) 255 UK-Eth Black -0.02 (40.10, 0.07) 247 US-Mayo-White -0.00 (40.15, 0.07) 248 UK-Eth-White -0.00 (40.15, 0.07) 247 US-Mayo-White -0.00 (40.15, 0.07) 247 US-Mayo-White -0.00 (40.15, 0.07) 248 UK-Eth-White -0.00 (40.15, 0.07) 248 UK-Eth-South Asian -0.00 (40.15, 0.15) 252 UK-Eth-South Asian 0.00 (-0.07, 0.08) 893 Turkey -0.01 (-0.13, 0.15) 452 UK-Eth-South Asian 0.02 (-0.14, 0.17) 117 Malaysia-Malay 0.02 (-0.14, 0.18) 270 Singapore-Chinese 0.02 (-0.04, 0.12) 423 Malaysia-Chinese 0.04 (-0.06, 0.14) 467 Poland -0.05 (-0.06, 0.17) 428 Korea -0.06 (-0.02, 0.13) 448 Canada -0.08 (-0.09, 0.25) 274 UK-Age Trial-White -0.11 (-0.03, 0.23) 159	Eqvpt	-0.04 (-0.15, 0.07)	562
Netherlands -0.03 (0.12, 0.07) 418 Singapore-Malay -0.02 (0.11, 0.07) 235 UK-Eth Black -0.02 (0.16, 0.13) 253 Singapore-Indian -0.02 (0.14, 0.15) 281 UK-Eth Black -0.00 (0.13, 0.12) 458 UK-Eth-White -0.00 (0.13, 0.12) 458 UK-Eth-White -0.00 (0.13, 0.12) 458 Spain 0.00 (0.14, 0.15) 281 Turkey 0.01 (-0.13, 0.15) 452 UK-Eth-South Asian 0.02 (0.14, 0.17) 117 Malaysia-Malay 0.02 (-0.14, 0.18) 270 Singapore-Chinese 0.02 (-0.08, 0.11) 213 Norway 0.03 (-0.12, 0.18) 242 US-MEC-White 0.03 (-0.12, 0.18) 242 US-MEC-White 0.03 (-0.12, 0.18) 448 Canada 0.04 (-0.06, 0.14) 467 Poland 0.05 (-0.06, 0.17) 482 Korea 0.06 (-0.02, 0.13) 448 Canada 0.08 (-0.09, 0.25) 288 Japan 0.10 (-0.03, 0.23) 159 US-MEC-Hawaiian 0.10 (-0.03, 0.23)	Kenva	-0.04 (-0.15, 0.07)	268
Singapore-Malay -0.02 (-0.11, 0.07) 235 UK-Eth Black -0.02 (-0.11, 0.07) 247 US-Mayo-White -0.00 (-0.13, 0.12) 458 UK-Eth-White 0.00 (-0.08, 0.09) 461 Spain 0.00 (-0.07, 0.08) 893 Turkey 0.01 (-0.13, 0.12) 452 UK-Eth-South Asian 0.02 (-0.14, 0.17) 117 Malaysia-Malay 0.02 (-0.14, 0.17) 117 Malaysia-Malay 0.02 (-0.14, 0.18) 270 Singapore-Chinese 0.02 (-0.08, 0.11) 213 Norway 0.03 (-0.12, 0.18) 242 US-MEC-White 0.03 (-0.14, 0.20) 181 South Africa 0.04 (-0.06, 0.11) 213 Malaysia-Indian 0.08 (-0.02, 0.13) 448 Canada 0.08 (-0.09, 0.22) 377 Malaysia-Indian 0.10 (-0.03, 0.23) 159 US-MEC-Hawaiian 0.11 (-0.03, 0.23) 159 US-MEC-Iapanese 0.22 (0.12, 0.31) 293 Australia-Italian 0.22 (0.12, 0.31) 293 US-MEC-Japanese 0.22 (0.12, 0.31) 293 A	Netherlands	-0.03 (-0.12, 0.07)	418
UK-Eh Black -0.02 (-0.16, 0.13) 253 Singapore-Indian -0.02 (-0.16, 0.13) 254 UK-Eh White -0.00 (-0.13, 0.12) 458 UK-Eh White 0.00 (-0.14, 0.15) 281 Iran 0.00 (-0.08, 0.09) 461 Spain 0.00 (-0.13, 0.12) 458 UK-Eh-White 0.00 (-0.08, 0.09) 461 Spain 0.00 (-0.13, 0.12) 452 UK-Eh-South Asian 0.02 (-0.14, 0.15) 452 UK-Eh-South Asian 0.02 (-0.14, 0.18) 270 Singapore-Chinese 0.02 (-0.14, 0.12) 113 Norway 0.03 (-0.12, 0.18) 242 US-MEC-White 0.03 (-0.14, 0.20) 181 South Africa 0.04 (-0.06, 0.11) 467 Poland 0.05 (-0.06, 0.17) 492 Korea 0.06 (-0.02, 0.13) 448 Canada 0.08 (-0.06, 0.22) 377 Malaysia-Indian 0.08 (-0.06, 0.22) 377 Malaysia-Indian 0.08 (-0.06, 0.22) 328 Japan 0.11 (-0.02, 0.23) 159 US-MEC-Hawaiian 0.11 (-0.02, 0	Singapore-Malay	-0.02 (-0.11, 0.07)	235
Singapore-Indian -0.02 (-0.10, 0.07) 247 US-Mayo-White -0.00 (-0.13, 0.12) 458 UK-Eth-White 0.00 (-0.08, 0.09) 461 Spain 0.00 (-0.07, 0.08) 893 Turkey 0.01 (-0.13, 0.15) 452 UK-Eth-South Asian 0.02 (-0.14, 0.17) 117 Malaysia-Malay 0.02 (-0.14, 0.17) 117 Singapore-Chinese 0.02 (-0.04, 0.18) 270 Singapore-Chinese 0.02 (-0.04, 0.18) 242 US-MEC-White 0.03 (-0.14, 0.20) 181 South Africa 0.04 (-0.04, 0.12) 423 Malaysia-Chinese 0.04 (-0.06, 0.21) 171 Poland 0.06 (-0.02, 0.13) 448 Canada 0.08 (-0.06, 0.22) 377 Malaysia-Indian 0.08 (-0.06, 0.22) 377 Japan 0.11 (-0.02, 0.23) 159 US-MEC-Hawaiian 0.11 (-0.02, 0.23) 256 Identified 0.13 (-0.06, 0.32) 169 US-MEC-Hawaiian 0.11 (-0.02, 0.23) 256 Identified 0.11 (-0.02, 0.23) 256 Chile			253
US-Mayo-White -0.00 (0.13, 0.12) 458 UK-Eth-White -0.00 (0.13, 0.12) 458 Iran 0.00 (-0.08, 0.09) 461 Spain 0.00 (-0.07, 0.08) 893 Turkey 0.01 (-0.13, 0.12) 452 UK-Eth-South Asian 0.02 (-0.14, 0.17) 117 Malaysia-Malay 0.02 (-0.14, 0.18) 270 Singapore-Chinese 0.02 (-0.08, 0.11) 213 Norway 0.03 (-0.12, 0.12) 421 US-MEC-White 0.03 (-0.14, 0.20) 181 South Africa 0.04 (-0.06, 0.17) 422 Malaysia-Chinese 0.04 (-0.06, 0.17) 422 Variation 0.05 (-0.06, 0.17) 492 Korea 0.06 (-0.02, 0.13) 448 Canada 0.08 (-0.09, 0.25) 288 Japan 0.10 (-0.03, 0.23) 159 US-MEC-Hawaiian 0.11 (-0.03, 0.25) 274 Ikrael-Jewish 0.11 (-0.03, 0.25) 274 UK-Age Trial-White 0.13 (-0.06, 0.32) 197 US-MEC-Japanese 0.22 (0.12, 0.31) 293 Australia-Italian 0.	Singapore-Indian		247
UK-Eth-White 0.00 (-0.14, 0.15) 281 Iran 0.00 (-0.08, 0.09) 461 Spain 0.00 (-0.07, 0.08) 893 Turkey 0.01 (-0.13, 0.15) 452 UK-Eth-South Asian 0.02 (-0.14, 0.15) 452 UK-Eth-South Asian 0.02 (-0.14, 0.17) 117 Malaysia-Malay 0.02 (-0.14, 0.18) 270 Singapore-Chinese 0.02 (-0.14, 0.18) 242 US-MEC-White 0.03 (-0.12, 0.18) 242 US-MEC-White 0.03 (-0.14, 0.20) 181 South Africa 0.04 (-0.06, 0.14) 467 Poland 0.05 (-0.06, 0.17) 492 Korea 0.06 (-0.02, 0.13) 448 Canada 0.08 (-0.06, 0.22) 377 Malaysia-Indian 0.08 (-0.06, 0.22) 377 Malaysia-Indian 0.08 (-0.07, 0.27) 158 Israel-Jewish 0.11 (-0.07, 0.29) 332 Hong Kong 0.11 (-0.03, 0.25) 274 UK-Age Trial-White 0.13 (-0.66, 0.32) 197 US-MEC-Japanese 0.22 (0.12, 0.31) 293 Australia-Italian		-0.00 (-0.13, 0.12)	458
Iran 0.00 (-0.08, 0.09) 461 Spain 0.00 (-0.07, 0.08) 893 Turkey 0.01 (-0.13, 0.15) 452 UK-Eth-South Asian 0.02 (-0.14, 0.17) 117 Malaysia-Malay 0.02 (-0.08, 0.09) 461 Singapore-Chinese 0.02 (-0.14, 0.18) 270 Singapore-Chinese 0.02 (-0.08, 0.11) 213 Norway 0.03 (-0.12, 0.18) 242 US-MEC-White 0.03 (-0.14, 0.20) 181 South Africa 0.04 (-0.06, 0.14) 467 Poland 0.05 (-0.06, 0.07) 492 Korea 0.06 (-0.02, 0.13) 448 Canada 0.08 (-0.06, 0.22) 377 Malaysia-Indian 0.08 (-0.06, 0.22) 377 Malaysia-Indian 0.10 (0.00, 0.19) 454 Mexico 0.11 (-0.03, 0.23) 159 US-MEC-Hawaiian 0.10 (-0.03, 0.23) 159 Israel-Jewish 0.11 (-0.03, 0.25) 274 UK-Age Trial-White 0.13 (-0.06, 0.32) 197 US-MEC-Japanese 0.22 (0.13, 0.44) 211 Australia-Italian <td< td=""><td>UK-Eth-White</td><td>0.00 (-0.14, 0.15)</td><td>281</td></td<>	UK-Eth-White	0.00 (-0.14, 0.15)	281
Spain 0.00 (-0.07, 0.08) 893 Turkey 0.01 (-0.13, 0.15) 452 UK-Eth-South Asian 0.02 (-0.14, 0.17) 117 Malaysia-Malay 0.02 (-0.14, 0.18) 270 Singapore-Chinese 0.02 (-0.14, 0.18) 242 US-MEC-White 0.03 (-0.12, 0.18) 242 US-MEC-White 0.03 (-0.14, 0.20) 181 South Africa 0.04 (-0.06, 0.14) 467 Poland 0.05 (-0.06, 0.17) 492 Korea 0.06 (-0.02, 0.13) 448 Canada 0.08 (-0.06, 0.22) 377 Malaysia-Indian 0.08 (-0.06, 0.22) 377 Malaysia-Indian 0.08 (-0.00, 0.19) 454 Mexico 0.10 (-0.03, 0.23) 159 US-MEC-Hawaiian 0.10 (-0.03, 0.23) 256 Israel-Jewish 0.11 (-0.02, 0.23) 226 Chile 0.11 (-0.03, 0.25) 274 UK-Age Trial-White 0.13 (-0.06, 0.32) 197 US-USC-Black 0.22 (0.12, 0.31) 293 Australia-Italian 0.28 (0.13, 0.44) 211 Overall (I-squared = 32.4%,	Iran —		461
Turkey 0.01 (-0.13, 0.15) 452 UK-Eth-South Asian 0.02 (-0.14, 0.17) 117 Malaysia-Malay 0.02 (-0.14, 0.18) 270 Singapore-Chinese 0.02 (-0.14, 0.18) 242 US-MEC-White 0.03 (-0.12, 0.18) 242 US-MEC-White 0.03 (-0.14, 0.20) 181 South Africa 0.04 (-0.06, 0.14) 467 Poland 0.05 (-0.06, 0.17) 492 Korea 0.06 (-0.02, 0.13) 448 Canada 0.08 (-0.06, 0.22) 377 Malaysia-Indian 0.08 (-0.09, 0.25) 288 Japan 0.10 (0.00, 0.19) 454 Mexico 0.10 (-0.07, 0.27) 158 US-MEC-Hawaiian 0.11 (-0.07, 0.29) 332 Hong Kong 0.11 (-0.07, 0.34) 129 US-MEC-Japanese 0.22 (0.12, 0.31) 293 Australia-Italian 0.28 (0.13, 0.44) 211 Overall (I-squared = 32.4%, p = 0.029) 0.03 (0.01, 0.05) 0.03 (0.01, 0.05)	Spain		893
UK-Eth-South Asian 0.02 (-0.14, 0.17) 117 Malaysia-Malay 0.02 (-0.14, 0.17) 117 Singapore-Chinese 0.02 (-0.14, 0.18) 270 Singapore-Chinese 0.02 (-0.14, 0.18) 270 Norway 0.03 (-0.12, 0.18) 242 US-MEC-White 0.03 (-0.12, 0.18) 242 South Africa 0.04 (-0.06, 0.14) 267 Poland 0.05 (-0.06, 0.17) 492 Korea 0.06 (-0.02, 0.13) 448 Canada 0.08 (-0.06, 0.22) 377 Malaysia-Indian 0.08 (-0.06, 0.22) 377 Malaysia-Indian 0.08 (-0.00, 0.19) 454 Japan 0.10 (0.00, 0.19) 454 Mexico 0.10 (-0.07, 0.27) 158 US-MEC-Hawaiian 0.11 (-0.07, 0.23) 226 Chile 0.11 (-0.07, 0.34) 129 US-MEC-Japanese 0.22 (0.12, 0.31) 293 Australia-Italian 0.28 (0.13, 0.44) 211 Overall (I-squared = 32.4%, p = 0.029) 0.03 (0.01, 0.05) 0.03 (0.01, 0.05)		0.01 (-0.13, 0.15)	452
Malaysia-Malay 0.02 (-0.14, 0.18) 270 Singapore-Chinese 0.02 (-0.14, 0.18) 270 Norway 0.03 (-0.12, 0.18) 242 US-MEC-White 0.03 (-0.12, 0.18) 242 South Africa 0.04 (-0.04, 0.12) 423 Malaysia-Chinese 0.04 (-0.06, 0.14) 467 Poland 0.05 (-0.06, 0.17) 492 Korea 0.06 (-0.02, 0.13) 448 Canada 0.08 (-0.06, 0.22) 377 Malaysia-Indian 0.08 (-0.06, 0.22) 377 Malaysia-Indian 0.08 (-0.00, 0.19) 454 Japan 0.10 (0.00, 0.19) 454 Mexico 0.10 (-0.07, 0.27) 158 US-MEC-Hawaiian 0.11 (-0.07, 0.29) 332 Hong Kong 0.11 (-0.07, 0.34) 129 UK-Age Trial-White 0.13 (-0.06, 0.32) 197 US-MEC-Japanese 0.22 (0.12, 0.31) 293 Australia-Italian 0.22 (0.12, 0.31) 293 Overall (I-squared = 32.4%, p = 0.029) 0.03 (0.01, 0.05) 0.03 (0.01, 0.05)	LIK-Eth-South Asian		117
Singapore-Chinese 0.02 (-0.08, 0.11) 213 Norway 0.03 (-0.12, 0.18) 242 US-MEC-White 0.03 (-0.14, 0.20) 181 South Africa 0.04 (-0.04, 0.12) 423 Malaysia-Chinese 0.04 (-0.06, 0.14) 467 Poland 0.05 (-0.06, 0.17) 492 Korea 0.06 (-0.02, 0.13) 448 Canada 0.08 (-0.06, 0.22) 377 Malaysia-Indian 0.08 (-0.09, 0.25) 288 Japan 0.10 (-0.03, 0.23) 159 US-MEC-Hawaiian 0.10 (-0.07, 0.27) 158 Israel-Jewish 0.11 (-0.07, 0.29) 332 Hong Kong 0.11 (-0.07, 0.34) 129 US-MEC-Japanese 0.22 (0.12, 0.31) 293 Australia-Italian 0.22 (0.12, 0.31) 293 Overall (I-squared = 32.4%, p = 0.029) 0.03 (0.01, 0.05) 0.03 (0.01, 0.05)	Malavsia-Malav	0.02 (-0.14, 0.18)	270
Norway 0.03 (-0.12, 0.18) 242 US-MEC-White 0.03 (-0.14, 0.20) 181 South Africa 0.04 (-0.04, 0.12) 423 Malaysia-Chinese 0.04 (-0.06, 0.14) 467 Poland 0.05 (-0.06, 0.17) 492 Korea 0.06 (-0.02, 0.13) 448 Canada 0.08 (-0.06, 0.22) 377 Malaysia-Indian 0.08 (-0.09, 0.25) 288 Japan 0.10 (-0.03, 0.23) 159 US-MEC-Hawaiian 0.10 (-0.07, 0.27) 158 Israel-Jewish 0.11 (-0.07, 0.29) 332 Hong Kong 0.11 (-0.07, 0.34) 129 US-MEC-Japanese 0.22 (0.12, 0.31) 293 Australia-Italian 0.28 (0.13, 0.44) 211 Overall (I-squared = 32.4%, p = 0.029) 0.03 (0.01, 0.05) 0.03 (0.01, 0.05)	Singapore-Chinese		213
US-MEC-White 0.03 (-0.14, 0.20) 181 South Africa 0.04 (-0.04, 0.12) 423 Malaysia-Chinese 0.04 (-0.06, 0.14) 467 Poland 0.05 (-0.06, 0.17) 492 Korea 0.06 (-0.02, 0.13) 448 Canada 0.08 (-0.09, 0.25) 288 Japan 0.10 (-0.03, 0.23) 159 US-MEC-Hawaiian 0.10 (-0.07, 0.27) 158 Israel-Jewish 0.11 (-0.07, 0.29) 332 Hong Kong 0.11 (-0.03, 0.25) 274 UK-Age Trial-White 0.13 (-0.06, 0.32) 197 US-MEC-Japanese 0.22 (0.12, 0.31) 293 Australia-Italian 0.28 (0.13, 0.44) 211 Overall (I-squared = 32.4%, p = 0.029) 0.3 (0.01, 0.05) 0.3 (0.01, 0.05)	Norway	0.03 (-0.12, 0.18)	242
South Africa 0.04 (-0.04, 0.12) 423 Malaysia-Chinese 0.04 (-0.06, 0.14) 467 Poland 0.05 (-0.06, 0.17) 492 Korea 0.06 (-0.02, 0.13) 448 Canada 0.08 (-0.09, 0.25) 288 Japan 0.10 (-0.03, 0.23) 159 US-MEC-Hawaiian 0.10 (-0.07, 0.27) 158 Israel-Jewish 0.11 (-0.07, 0.29) 332 Hong Kong 0.11 (-0.03, 0.25) 274 UK-Age Trial-White 0.13 (-0.06, 0.32) 197 US-MEC-Japanese 0.22 (0.12, 0.31) 293 Australia-Italian 0.28 (0.13, 0.44) 211 Overall (I-squared = 32.4%, p = 0.029) 0.33 (0.01, 0.05) 111	US-MEC-White	0.03 (-0.14, 0.20)	181
Malaysia-Chinese 0.04 (-0.06, 0.14) 467 Poland 0.05 (-0.06, 0.17) 492 Korea 0.06 (-0.02, 0.13) 448 Canada 0.08 (-0.06, 0.22) 377 Malaysia-Indian 0.08 (-0.09, 0.25) 288 Japan 0.10 (0.00, 0.19) 454 Mexico 0.10 (-0.07, 0.27) 158 US-MEC-Hawaiian 0.10 (-0.07, 0.27) 158 Israel-Jewish 0.11 (-0.07, 0.29) 332 Hong Kong 0.11 (-0.07, 0.29) 332 Chile 0.11 (-0.07, 0.34) 129 US-MEC-Japanese 0.22 (0.12, 0.31) 293 Australia-Italian 0.28 (0.13, 0.44) 211 Overall (I-squared = 32.4%, p = 0.029) 0.03 (0.01, 0.05) 0.03 (0.01, 0.05)	South Africa		423
Poland 0.05 (-0.06, 0.17) 492 Korea 0.06 (-0.02, 0.13) 448 Canada 0.08 (-0.06, 0.22) 377 Malaysia-Indian 0.08 (-0.09, 0.25) 288 Japan 0.10 (0.00, 0.19) 454 Mexico 0.10 (-0.03, 0.23) 159 US-MEC-Hawaiian 0.10 (-0.07, 0.27) 158 Israel-Jewish 0.11 (-0.07, 0.29) 332 Hong Kong 0.11 (-0.03, 0.25) 274 UK-Age Trial-White 0.13 (-0.06, 0.32) 197 US-USC-Black 0.14 (-0.07, 0.34) 129 US-MEC-Japanese 0.22 (0.12, 0.31) 293 Australia-Italian 0.28 (0.13, 0.44) 211 Overall (I-squared = 32.4%, p = 0.029) 0.03 (0.01, 0.05) 0.03 (0.01, 0.05)	Malaysia-Chinese		467
Korea 0.06 (-0.02, 0.13) 448 Canada 0.08 (-0.06, 0.22) 377 Malaysia-Indian 0.08 (-0.09, 0.25) 288 Japan 0.10 (0.00, 0.19) 454 Mexico 0.10 (-0.03, 0.23) 159 US-MEC-Hawaiian 0.10 (-0.07, 0.27) 158 Israel-Jewish 0.11 (-0.07, 0.29) 332 Hong Kong 0.11 (-0.03, 0.25) 274 UK-Age Trial-White 0.13 (-0.06, 0.32) 197 US-USC-Black 0.14 (-0.07, 0.34) 129 US-MEC-Japanese 0.22 (0.12, 0.31) 293 Australia-Italian 0.28 (0.13, 0.44) 211 Overall (I-squared = 32.4%, p = 0.029) 0.03 (0.01, 0.05) 111	Poland		492
Canada 0.08 (-0.06, 0.22) 377 Malaysia-Indian 0.08 (-0.09, 0.25) 288 Japan 0.10 (0.00, 0.19) 454 Mexico 0.10 (-0.03, 0.23) 159 US-MEC-Hawaiian 0.10 (-0.07, 0.27) 158 Israel-Jewish 0.11 (-0.07, 0.29) 332 Hong Kong 0.11 (-0.02, 0.23) 226 Chile 0.11 (-0.03, 0.25) 274 UK-Age Trial-White 0.13 (-0.06, 0.32) 197 US-MEC-Japanese 0.22 (0.12, 0.31) 293 Australia-Italian 0.28 (0.13, 0.44) 211 Overall (I-squared = 32.4%, p = 0.029) 0.03 (0.01, 0.05) 0.03 (0.01, 0.05)	Korea		448
Malaysia-Indian 0.08 (-0.09, 0.25) 288 Japan 0.10 (0.00, 0.19) 454 Mexico 0.10 (-0.03, 0.23) 159 US-MEC-Hawaiian 0.10 (-0.07, 0.27) 158 Israel-Jewish 0.11 (-0.02, 0.23) 226 Hong Kong 0.11 (-0.02, 0.23) 226 Chile 0.11 (-0.02, 0.23) 226 UK-Age Trial-White 0.13 (-0.06, 0.32) 197 US-MEC-Japanese 0.22 (0.12, 0.31) 293 Australia-Italian 0.28 (0.13, 0.44) 211 Overall (I-squared = 32.4%, p = 0.029) 0.03 (0.01, 0.05) 0.03 (0.01, 0.05)	Canada		377
Japan 0.10 (0.00, 0.19) 454 Mexico 0.10 (-0.03, 0.23) 159 US-MEC-Hawaiian 0.10 (-0.07, 0.27) 158 Israel-Jewish 0.11 (-0.07, 0.29) 332 Hong Kong 0.11 (-0.03, 0.25) 274 UK-Age Trial-White 0.13 (-0.06, 0.32) 197 US-MEC-Japanese 0.22 (0.12, 0.31) 293 Australia-Italian 0.28 (0.13, 0.44) 211 Overall (I-squared = 32.4%, p = 0.029) 0.03 (0.01, 0.05) 0.03 (0.01, 0.05)	Malaysia-Indian		288
Mexico 0.10 (-0.03, 0.23) 159 US-MEC-Hawaiian 0.10 (-0.07, 0.27) 158 Israel-Jewish 0.11 (-0.07, 0.29) 332 Hong Kong 0.11 (-0.02, 0.23) 226 Chile 0.11 (-0.03, 0.25) 274 UK-Age Trial-White 0.13 (-0.06, 0.32) 197 US-USC-Black 0.14 (-0.07, 0.34) 129 US-MEC-Japanese 0.22 (0.12, 0.31) 293 Australia-Italian 0.28 (0.13, 0.44) 211 Overall (I-squared = 32.4%, p = 0.029) 0.03 (0.01, 0.05) 0.03 (0.01, 0.05)	Janan		454
US-MEC-Hawaiian 0.10 (0.03, 0.20) 100 Israel-Jewish 0.10 (-0.07, 0.27) 158 Hong Kong 0.11 (-0.02, 0.23) 226 Chile 0.11 (-0.03, 0.25) 274 UK-Age Trial-White 0.13 (-0.06, 0.32) 197 US-MEC-Japanese 0.22 (0.12, 0.31) 293 Australia-Italian 0.28 (0.13, 0.44) 211 Overall (I-squared = 32.4%, p = 0.029) 0.3 (0.01, 0.05) 0.3 (0.01, 0.05)	Mexico		159
Israel-Jewish 0.10 (0.07, 0.27) 100 Israel-Jewish 0.11 (-0.07, 0.29) 332 Hong Kong 0.11 (-0.02, 0.23) 226 Chile 0.11 (-0.03, 0.25) 274 UK-Age Trial-White 0.13 (-0.06, 0.32) 197 US-USC-Black 0.14 (-0.07, 0.34) 129 US-MEC-Japanese 0.22 (0.12, 0.31) 293 Australia-Italian 0.28 (0.13, 0.44) 211 Overall (I-squared = 32.4%, p = 0.029) 0.03 (0.01, 0.05) 0.03 (0.01, 0.05)			158
Hong Kong 0.11 (-0.02, 0.23) 226 Chile 0.11 (-0.03, 0.25) 274 UK-Age Trial-White 0.13 (-0.06, 0.32) 197 US-USC-Black 0.14 (-0.07, 0.34) 129 US-MEC-Japanese 0.22 (0.12, 0.31) 293 Australia-Italian 0.28 (0.13, 0.44) 211 Overall (I-squared = 32.4%, p = 0.029) 0.03 (0.01, 0.05) 0.03 (0.01, 0.05)	Israel- lewish		332
Chile 0.11 (-0.03, 0.25) 274 UK-Age Trial-White 0.13 (-0.06, 0.32) 197 US-USC-Black 0.14 (-0.07, 0.34) 129 US-MEC-Japanese 0.22 (0.12, 0.31) 293 Australia-Italian 0.28 (0.13, 0.44) 211 Overall (I-squared = 32.4%, p = 0.029) 0.03 (0.01, 0.05) 0.03 (0.01, 0.05)	Hong Kong		226
UK-Age Trial-White 0.13 (-0.06, 0.32) 197 US-USC-Black 0.14 (-0.07, 0.34) 129 US-MEC-Japanese 0.22 (0.12, 0.31) 293 Australia-Italian 0.28 (0.13, 0.44) 211 Overall (I-squared = 32.4%, p = 0.029) 0.03 (0.01, 0.05) 0.03 (0.01, 0.05)	Chile		274
US-MEC-Japanese Australia-Italian Overall (I-squared = 32.4%, p = 0.029)	UK-Age Trial-White		197
US-MEC-Japanese 0.22 (0.12, 0.31) 293 Australia-Italian 0.28 (0.13, 0.44) 211 Overall (I-squared = 32.4%, p = 0.029) 0.03 (0.01, 0.05)	US-USC-Black		129
Australia-Italian 0.28 (0.12, 0.01) 200 Overall (I-squared = 32.4%, p = 0.029) 0.03 (0.01, 0.05)	US-MEC-Japanese		293
Overall (I-squared = 32.4%, p = 0.029) 0.03 (0.01, 0.05)	Australia-Italian		211
	Overall (I-squared = 32.4%, p = 0.029)	0.03 (0.01, 0.05)	
Random effects analysis	Random effects analysis		

Fig. 2 Association of age at menarche (per year) with dense area. Forest plot depicting results from a meta-analysis of the association of age at menarche (per year) with square-root dense area of the breast, in studies from the International Consortium on Mammographic Density. Effect estimates for each separate population group are shown, as well as the combined effect estimate, from random effects model

possible independent effects of each exposure of interest, models for age at menarche were additionally adjusted for height and models for height were additionally adjusted for age at menarche.

Subgroup analyses by menopausal status, parity, BMI category and anthropometric ascertainment method were also performed using the multi-level pooled models. An additional adjustment for age at first birth was included for parous subsets.

Sensitivity analyses

We also performed sensitivity analyses adjusting for a population-specific weight-for-height index, instead of BMI, as BMI and height are inversely correlated. Whilst BMI aims to be a measure of weight independent of height, it is a simplified index and is not completely independent of height [23]. The weight-height relationship has been shown to vary according to age and gender, such that height is inversely associated with BMI in (white) adults, but the magnitude of the association is larger for women and increases with age [24]. The weight-height relationship may differ in an international study where body sizes and shapes differ, and it is therefore important to examine MD associations with height independent of BMI or body fatness. Additional analyses were conducted to take these potential issues into account, using a weight-for-height index that was defined as the ratio of an individual's weight to their population-specific expected weight. The expected weight was generated using a population group-specific relationship of weight as a function of $k_1 \times \text{height } k^2$ where both k_1 and k_2 were optimized separately for each population group. The median value of k_2 was 1.30 (inter-quartile range [IQR] 1.19-1.35; Additional file 1: Table S1), which is lower than the power of 2 which is used in BMI (i.e. weight/ height²).

Results

Participant characteristics

Characteristics of the participants, overall and by ethnic group, are shown in Table 1. The mean age at mammogram was 52.7 years (standard deviation (SD) = 8.2 years), which was relatively consistent across all groups except the Mestizo women, who were, on average, approximately 10 years younger. The mean age at menarche was also similar across all ethnic groups and, on average, occurred at a 13.2 years (SD=1.7 years). Height varied slightly across the ethnic groups, with average height notably shorter in the East Asian, South Asian and Mestizo groups. There were more

post-menopausal than pre-menopausal women in all ethnic groups except the Mestizo group, consistent with their younger age, and there were substantially more parous (90%) than nulliparous (10%) women.

Age at menarche

Forest plots depicting population group-specific associations for age at menarche with each of the MD measures, along with meta-analyses results for overall associations, are presented in Figs. 1 (PD) and 2 (DA). Overall, a small positive association was observed between the squareroot change in both PD (β =0.02, 95% CI 0.00, 0.03) and DA (β =0.03, 95% CI 0.01, 0.05) with each yearly increase in age at menarche. Results were highly consistent across all studies for \sqrt{PD} (I^2 =12.1%) but less so for \sqrt{DA} (I^2 =32.4%), although both were considered to have low heterogeneity overall.

Pooled analyses of all participants (Table 2) showed very similar overall effect estimates to the meta-analyses. Later age at menarche was associated with increased \sqrt{PD} in all women (β =0.057, SE=0.008, P<0.001). Results were attenuated when adjusted for BMI (β =0.023, SE=0.008, P=0.003), similar to meta-analysis estimates. Adjustment for height did not alter the effect estimate substantially. Stratified analyses showed that this association was primarily driven by women with a BMI under 25 kg/m² and by parous women. The association was present at both pre- and post-menopausal ages.

Similar results were observed for DA; later age at menarche was also associated with an increase in \sqrt{DA} for all women ($\beta = 0.032$, SE = 0.010, P = 0.002). The association with \sqrt{DA} was also more evident in parous women and women with lower BMI (BMI ≤ 25 : P < 0.001) and did not differ by menopausal status. Results were generally unaffected after adjusting for age at first birth or age at menopause.

Height

Population group-specific and meta-analyses results for the association of MD measures with height are shown in Figs. 3 (PD) and 4 (DA). Overall, there was no strong evidence of an association between \sqrt{PD} and height across studies ($\beta = -0.04$ per 10 cm height increment, 95% CI – 0.08, 0.01), but there was evidence of an overall increase for \sqrt{DA} per 10 cm increase in height ($\beta = 0.08, 95\%$ CI 0.02, 0.14). Heterogeneity across population groups was relatively low for each MD measure (\sqrt{PD} , $l^2 = 22.6\%$; \sqrt{DA} , $l^2 = 20.9\%$).

(See figure on next page.)

Fig. 3 Association of adult height (per 10 cm increment) with per cent density. Forest plot depicting results from a meta-analysis of the association of adult height (per 10 cm increment) with square-root per cent density of the breast, in studies from the International Consortium on Mammographic Density. Effect estimates for each separate population group are shown, as well as the combined effect estimate, from random effects model

Study	Change in square-root PD (95% CI)	No. women
US-USC-Black	-0.36 (-0.66, -0.05)	129
US-Mayo-White	-0.26 (-0.47, -0.05)	458
US-USC-White	-0.22 (-0.49, 0.05)	178
US-MEC-White	-0.22 (-0.55, 0.11)	181
UK-Eth-South Asian	-0.20 (-0.47, 0.07)	117
US-MEC-Hawaiian	-0.20 (-0.60, 0.20)	158
Australia-Greek	-0.19 (-0.64, 0.25)	160
Turkey	-0.18 (-0.38, 0.02)	452
Israel-Jewish	-0.18 (-0.43, 0.07)	332
Singapore-Malay	-0.16 (-0.38 0.06)	235
US-NHS-White	-0.15 (-0.36, 0.06)	485
Canada	-0.14 (-0.41 0.14)	377
		253
		454
		226
		220
		295
		274
South Africa		422
Baland		423
		492
		288
Australia-Australian		447
Korea	-0.04 (-0.25, 0.18)	448
UK-Eth-White		281
Australia-Italian	0.00 (-0.31, 0.32)	211
Spain —	0.02 (-0.14, 0.19)	893
Singapore-Indian	0.04 (-0.21, 0.28)	247
Singapore-Chinese	0.04 (-0.25, 0.34)	213
Israel-Arab	0.05 (-0.24, 0.34)	291
Egypt -	0.07 (-0.10, 0.24)	562
Malaysia-Malay ———	0.11 (-0.18, 0.40)	270
UK-Age Trial-White	0.11 (-0.21, 0.44)	197
Netherlands	0.13 (-0.07, 0.32)	418
Norway	0.16 (-0.16, 0.47)	242
Iran	0.17 (-0.01, 0.35)	461
Kenya	0.17 (-0.01, 0.35)	461
US-USC-Asian	0.20 (-0.28, 0.67)	59
UK-London-White	0.20 (-0.06, 0.46)	279
Mexico	0.24 (-0.03, 0.51)	159
Overall (I-squared = 22.6%, p = 0.107)	-0.04 (-0.08, 0.01)	
Random effects meta-analysis		

US-USC-White	-0.29 (-0.73 0.16) 178
Canada	-0.15 (-0.49, 0.20) 377
	-0.09 (-0.38, 0.20) 452
Malaysia-Chinese	-0.06 (-0.33, 0.21) 467
Singapore-Malay	-0.06 (-0.34, 0.23) 235
US-NHS-White	-0.06 (-0.34, 0.23) 485
	-0.03 (-0.52, 0.46) 158
South Africa	
UK-Eth Black	
Israel-Jewish	0.02 (-0.32, 0.36) 332
Hona Kona	0.03 (-0.35, 0.41) 226
Singapore-Chinese	0.03 (-0.31, 0.37) 213
US-MEC-Japanese	0.04 (-0.24, 0.31) 293
Japan	0.04 (-0.24, 0.31) 454
Australia-Australian —	0.05 (-0.26, 0.35) 447
Malavsia-Indian	0.05 (-0.33, 0.43) 288
Singapore-Indian	0.06 (-0.25, 0.37) 247
Poland	0.08 (-0.25, 0.41) 492
Korea	0.09 (-0.16, 0.34) 448
Spain	0.11 (-0.10, 0.32) 893
Australia-Italian —	0.11 (-0.31, 0.52) 211
US-USC-Black	0.13 (-0.38, 0.65) 129
Malaysia-Malay —	0.15 (-0.24, 0.55) 270
Norway -	0.18 (-0.20, 0.56) 242
UK-Eth-White	0.21 (-0.15, 0.56) 281
Netherlands	0.25 (0.01, 0.50) 418
UK-Age Trial-White	0.27 (-0.17, 0.71) 197
Mexico	0.28 (-0.14, 0.71) 159
UK-London-White	0.30 (-0.03, 0.64) 279
Israel-Arab	0.32 (-0.10, 0.74) 291
Egypt	0.36 (0.09, 0.62) 562
Iran	0.46 (0.20, 0.71) 461
Kenya	0.46 (0.20, 0.71) 461
US-USC-Asian —	0.52 (-0.26, 1.30) 59
Overall (I-squared = 20.9%, p = 0.127)	0.08 (0.02, 0.14)

Fig. 4 Association of adult height (per 10 cm increment) with dense area. Forest plot depicting results from a meta-analysis of the association of adult height (per 10 cm increment) with square-root dense area of the breast, in studies from the International Consortium on Mammographic Density. Effect estimates for each separate population group are shown, as well as the combined effect estimate, from random effects model

World Region ^a :	All women (<i>n</i> = 10,681)	White (<i>n</i> = 4512)	Black (<i>n</i> =938)	East Asian (<i>n</i> = 1837)	South Asian (<i>n</i> = 1133)	Mestizo (n=333)	Hawaiian (<i>n</i> = 142)	Middle Eastern (<i>n</i> = 1786)
	<i>n</i> [column %] unless stated o	otherwise					
Per cent density (cm ²)								
Median (IQR)	20 (11–31)	22 (16–35)	17 (10–26)	24 (16–35)	16 (8–25)	20 (13–27)	18 (9–32)	16 (8–24)
Dense area (cm ²)								
Median (IQR)	27 (16–41)	27 (17–42)	34 (20–49)	24 (15–35)	22 (12–35)	28 (18–42)	25 (12–38)	29 (16–43)
Age at mammo- gram (years)								
Mean (SD)	52.7 (8.2)	53.8 (7.7)	52.4 (8.5)	52.1(8.5)	53.6 (7.2)	44.2 (6.4)	55.1 (7.5)	51.4 (8.5)
IQR	47–58	49–59	46–58	45–58	49–59	40–49	50-61	45–57
Age at menarche (yrs) ^b								
< 12.0	1470 [14]	838 [19]	80 [9]	166 [9]	153 [14]	77 [23]	20 [14]	136 [8]
12.0-12.9	2588 [24]	1031 [23]	116 [12]	437 [24]	300 [26]	87 [26]	56 [39]	561 [31]
13.0-13.9	2594 [24]	1185 [26]	167 [18]	350 [19]	283 [25]	73 [22]	0 [0]	536 [30)
14.0-14.9	2023 [19]	848 [19]	182 [19]	425 [23]	165 [15]	46 [14]	47 [33]	310 [17]
<u>≥</u> 15.0	2006 [19]	610 [14]	393 [42]	459 [25]	232 [20]	50 [15]	19 [13]	243 [14]
Mean age (SD)	13.2 (1.7)	12.9 (1.6)	14.2 (2.1)	13.5 (1.8)	13.2 (1.7)	12.7 (1.7)	12.9 (1.8)	13.0 (1.4)
Height (cm)								
< 155	2760 [26]	685 [15]	186 [20]	704 [38]	663 [59]	113 [34]	17 [12]	392 [22]
155–159.9	2609 [24]	905 [20]	211 [22]	604 [33]	268 [24]	125 [38]	15 [11]	481 [27]
160–164.9	2759 [26]	1299 [29]	287 [31]	395 [22]	136 [12]	70 [21]	42 [30]	530 [30]
>165	2553 [24]	1623 [36]	254 [27]	134 [7]	66 [6]	25 [8]	68 [48]	383 [21]
Mean height (SD)	159.4 (7.2)	162.0 (6.9)	160.6 (7.6)	156.4 (5.6)	153.2 (6.8)	157.0 (5.3)	163.2 (6.0)	159.4 (6.3)
% of meas- ured heights ^c	66	57	39	57	85	98	0	100
BMI								
<u>≤</u> 20.0	642 (6)	208 (5)	9 (1)	284 (15)	95 (8)	3 (1)	2 (1)	41 (2)
20.1-25.0	3920 (37)	1787 (40)	171 (18)	1086 (59)	376 (33)	82 (25)	43 (30)	375 (21)
25.1-30.0	2342 (32)	1503 (33)	320 (34)	411 (22)	428 (38)	133 (40)	45 (32)	592 (33)
> 30.0	2687 (25)	1014 (22)	438 (47)	56 (3)	234 (21)	115 (35)	52 (37)	778 (44)
Mean BMI (SD)	27.0 (5.7)	26.7 (5.3)	30.3 (6.2)	23.2 (3.4)	26.3 (5.0)	28.7 (5.1)	28.9 (6.3)	29.6 (6.0)
Menopausal status								
Pre-meno- pausal	4361 [41]	1761 [39]	328 [35]	799 [43]	324 [29]	261 [78]	35 [25]	853 [48]
Post-meno- pausal	6320 [59]	2751 [61]	610 [65]	1038 [57]	809 [71]	72 [22]	107 [75]	933 [52]
Ever used hor- mone therapy ^d								
Yes	2185 [25]	1387 [36]	133 [14]	384 [21]	82 [8]	27 [8]	78 [55]	94 [12]
No	6681 [75]	2456 [64]	802 [86]	1425 [79]	969 [92]	291 [92]	64 [45]	674 [88]
Parity								
Nulliparous	1068 [10]	661 [15]	61 [7]	161 [9]	90 [8]	21 [6]	9 [6]	65 [4]
Parous	9613 [90]	3851 [85]	877 [94]	1,676 [91]	1,043 [92]	312 [94]	133 [94]	1721 [96]
Mean parity (SD)	2.6 (1.8)	2.4 (1.1)	3.3 (1.7)	2.5 (1.2)	3.9 (2.1)	2.9 (1.4)	3.3 (1.5)	3.6 (2.2)

Table 1 Characteristics of participants in the International Consortium on Mammographic Density

Table 1 (continued)

World Region ^a :	All women (<i>n</i> = 10,681)	White (<i>n</i> =4512)	Black (<i>n</i> =938)	East Asian (<i>n</i> = 1837)	South Asian (<i>n</i> = 1133)	Mestizo (n = 333)	Hawaiian (n = 142)	Middle Eastern (<i>n</i> = 1786)	
	n [column %] unless stated otherwise								
Age at first birth (yrs) ^b									
Mean age (SD)	24.3 (5.1)	25.3 (4.7)	22.3 (4.8)	26.2 (4.2)	22.4 (6.2)	23.9 (5.0)	22.9 (4.1)	22.5 (5.2)	
IQR	21–27.5	22–27.8	19–25	23–28.3	18–26	19.8–27	19–23	19–26	

BMI body mass index, cm centimetres, IQR inter-quartile range, SD standard deviation, yrs years

^a Population groups and study source, by world region

White: White women in Australia (3 studies—Australian, Greek and Italian born), Canada, Netherlands, Norway, Poland, Spain, the UK (3 studies) and the USA (mainland: 3 studies, Hawaii: 1 study)

Black: Black women in Kenya, South Africa, the UK and the USA

East Asian: Chinese women in Hong Kong, Malaysia and Singapore; Japanese women in Japan, Korea and the USA (mainland: 1 study, Hawaii: 1 study)

South Asian: Malay women in Malaysia and Singapore; Indian women in India, Malaysia, Singapore and the UK

Mestizo: Mestizo women in Chile and Mexico

Hawaiian: Hawaiian women in USA (Hawaii: 1 study)

Middle Eastern: Egyptian women in Egypt; Arab women in Israel; Jewish women in Iran, Israel and Turkey

^b Note raw data recorded categorically by some studies and subsequently converted to an approximated numerical value

^c Height data that were measured by the original study, as opposed to self-reported

^d Among women with non-missing data. Missing data on hormone therapy were 17% overall, < 4% for black, Hawaiian, Mestizo and East Asian, 15% missing for white women and 57% for Middle Eastern. These women were included in a missing-hormone-therapy category in later regression models

Pooled results for both measures of MD and their association with adult height are presented in Table 3. For height and PD, the association was positive without adjustment for BMI or when adjusted for the study-specific weight-for-height index (Additional file 1: Table S2), but inversely associated when adjusted for BMI. The latter appeared to reflect the strong inverse association of height and BMI in almost all population groups (Additional file 1: Table S1). In the stratified analyses (adjusted for BMI), the height- \sqrt{PD} associations were largely negative, regardless of parity or menopausal status. When subset by the method of height measurement, an association was only observed in those women who had self-reported their height.

Consistent with the meta-analysis, an increase was observed in \sqrt{DA} with increased height ($\beta = 0.059$, SE = 0.028, P = 0.034) and this association was slightly stronger without adjustment for BMI ($\beta = 0.069$, SE = 0.028, P = 0.012). When stratified by BMI category, women in all but the highest (> 30 kg/m²) categories had an increased \sqrt{DA} with increased height. When analysed by height ascertainment method, the height- \sqrt{DA} association was stronger when height was measured ($\beta = 0.084$, SE = 0.034, P = 0.015) as opposed to self-reported ($\beta = 0.020$, SE = 0.047, P = 0.676). The association with \sqrt{DA} was stronger in parous women, overall ($\beta = 0.090$, SE = 0.030, P = 0.002), and in both pre- ($\beta = 0.099$, SE = 0.047, P = 0.034) and post-menopausal parous women ($\beta = 0.090$, SE = 0.039, P = 0.019).

No differences in results were observed for any outcome measures when adjusted for age at first birth in parous women or age at menopause in the post-menopausal group.

Discussion

Within one of largest international MD studies consisting of populations with different ethnic backgrounds, we found that later age at menarche was positively associated with both per cent and absolute dense area and that increased height was positively associated with absolute dense area. Thus, the protective effect of later age at menarche on breast cancer risk is not likely mediated through MD. However, the increased risk of breast cancer associated with height could be mediated through MD, particularly DA. These results are consistent with previous findings [25] but are the first to demonstrate these associations across 22 different countries representing at least seven broad ethnic groups.

Earlier menarche is an established risk factor for breast cancer, perhaps explained by an increased number of regular menstrual cycles over the lifetime [1, 26]. As the relative amounts of epithelial, stromal and adipose tissue determine the radiological appearance of the adult breast, puberty is likely a key developmental stage in the establishment of MD [11]. As increased MD is associated with increased breast cancer risk, the paradoxical positive association between later menarche and MD is not

Table 2 Association of per cent density and dense area with age at menarche in pooled ICMD studies

	No. of women	No. of measurements	Per cent density ^a		Dense area ^{a, f}	
			Changes in square-root per cent density (SE)	P value	Changes in square- root dense area (SE)	P value
Age at menarche category (years)						
< 12.0	1470	1722	0		0	
12.0–12.9	2588	3036	0.006 (0.042)	0.889	— 0.032 (0.056)	0.575
13.0–13.9	2594	3067	0.064 (0.042)	0.130	0.053 (0.056)	0.346
14.0–14.9	2023	2397	0.057 (0.045)	0.207	0.034 (0.059)	0.569
≥ 15.0	2006	2364	0.128 (0.046)	0.005	0.166 (0.061)	0.007
Linear associations with a 1 year increase in age at menarche						
All women—Model A ^c						
All, BMI and height adjusted	10,681	12,586	0.023 (0.008)	0.003	0.032 (0.010)	0.002
All, without BMI adjustment	10,681	12,586	0.057 (0.008)	< 0.001	0.036 (0.010)	0.001
All, without height adjustment	10,681	12,586	0.022 (0.008)	0.004	0.033 (0.010)	0.001
Subset by BMI group (kg/m²)						
≤20.0	652	752	0.037 (0.032)	0.251		N/A ^b
20.1–25.0	3915	4585	0.039 (0.013)	0.002	0.068 (0.014)	< 0.001
25.1–30.0	3427	4048	0.013 (0.014)	0.328	0.005 (0.018)	0.782
> 30.0	2687	3201	0.012 (0.016)	0.456	0.009 (0.023)	0.704
Pre-menopausal women—Model B ^d						
All	4349	5135	0.020 (0.013)	0.122	0.028 (0.017)	0.111
Subset by parity						
Nulliparous women	483	558	— 0.044 (0.036)	0.226	0.009 (0.048)	0.847
Parous women	3866	4577	0.027 (0.013)	0.045	0.026 (0.018)	0.162
Parous women + age 1st birth adjustment	3866	4577	0.027 (0.013)	0.044	0.025 (0.018)	0.165
Post-menopausal women—Model C ^d						
All	5868	6902	0.022 (0.010)	0.029	0.029 (0.013)	0.029
All + age at menopause adjustment	5868	6902	0.022 (0.010)	0.031	0.029 (0.013)	0.031
Subset by parity						
Nulliparous women	535	626	0.005 (0.035)	0.891	0.022 (0.044)	0.623
Parous women	5333	6276	0.023 (0.011)	0.029	0.029 (0.014)	0.040
Parous women + age at 1st birth adjustment	5333	6276	0.021 (0.011)	0.051	0.026 (0.014)	0.064
Parous women + age at menopause adjustment	5333	6276	0.023 (0.011)	0.030	0.029 (0.014)	0.041
Parous women + ages at 1st birth + age at meno- pause adjustments	5333	6276	0.021 (0.011)	0.049	0.026 (0.014)	0.063
Nulliparous women—Model D ^e						
All	1068	1238	— 0.016 (0.025)	0.517	0.013 (0.033)	0.696
Parous women—Model E ^c						
All	9561	11,283	0.027 (0.008)	0.001	0.033 (0.011)	0.002
All + age at 1st birth adjustment	9561	11,283	0.026 (0.008)	0.001	0.033 (0.011)	0.003

BMI body mass index, ICMD International Consortium of Mammographic Density, SE standard error

^a A multi-level linear regression model was used to estimate the difference in square-root per cent density and dense area associated with each per year increase in age at menarche. Models specified correlations of women (level 1) within population groups (level 2)

 $^{\rm b}$ BMI \leq 20 category combined with BMI 20.1–25.0 categories due to lack of convergence

^c Models A (all women) and E (parous women): adjusted for age at mammogram³, menopausal status, age at mammogram^{*}menopausal status interaction term, BMI³, use of HRT, mammogram view, calibration, reader, parity, height

^d Models B (pre-menopausal women) and C (post-menopausal women): adjusted for age at mammogram³, BMI³, use of HRT, mammogram view, calibration, reader, parity, height

^e Model D (nulliparous women): adjusted for age at mammogram³, menopausal status, age at mammogram* menopausal status interaction term, BMI³, use of HRT, mammogram view, calibration, reader, height

^f Dense area models: BMI² adjusted for instead of BMI³

Table 3 Association of per cent density and dense area with adult height in pooled ICMD studies

	No. of	No. of measurements	Per cent density ^a		Dense area ^{a,e}	
	women		Changes in square-root per cent density (SE)	P value	Changes in square- root dense area (SE)	P value
Height (categorical) (cm)						
< 155	2718	3240	0		0	
155–159.9	2551	3027	- 0.041 (0.037)	0.259	0.048 (0.048)	0.319
160–164.9	2683	3151	- 0.056 (0.038)	0.141	0.096 (0.050)	0.057
≥165	2480	2900	- 0.075 (0.042)	0.076	0.118 (0.055)	0.034
Linear associations with a 10 cm increase in adult height All women—Model A ^b	t					
All, without BMI adjustment	10,432	12,318	0.044 (0.023)	0.054	0.069 (0.028)	0.012
All, without age at menarche adjustment	10,432	12,318	- 0.057 (0.021)	0.007	0.062 (0.028)	0.025
All, with BMI and menarche adjustment	10,432	12,318	- 0.060 (0.021)	0.005	0.059 (0.028)	0.034
By BMI strata: (kg/m ²)						
≤20.0	652	752	0.042 (0.075)	0.569	0.184 (0.073)	0.011
20.1–25.0	3882	4551	- 0.008 (0.034)	0.811	0.112 (0.041)	0.006
25.1–30.0	3328	3937	- 0.043 (0.037)	0.241	0.121 (0.050)	0.015
> 30.0	2570	3078	- 0.138 (0.040)	0.001	- 0.026 (0.060)	0.670
Subset by height measurement method						
Measured	7062	8389	- 0.040 (0.026)	0.125	0.084 (0.034)	0.015
Self-reported	3370	3929	- 0.096 (0.036)	0.007	0.020 (0.047)	0.676
Pre-menopausal women—Model B ^c						
All	4221	5000	- 0.049 (0.032)	0.130	0.074 (0.044)	0.092
Subset by parity						
Nulliparous women	478	553	- 0.201 (0.089)	0.024	— 0.012 (0.117)	0.922
Parous women	3743	4447	- 0.023 (0.034)	0.503	0.099 (0.047)	0.034
Parous women + age 1st birth adjustment	3743	4447	- 0.024 (0.034)	0.490	0.099 (0.047)	0.033
Post-menopausal women—Model C ^c						
All	5747	6769	- 0.067 (0.028)	0.017	0.047 (0.036)	0.201
All + age at menopause adjustment	5747	6769	- 0.070 (0.028)	0.013	0.043 (0.036)	0.239
Subset by parity						
Nulliparous women	531	622	- 0.144 (0.081)	0.076	- 0.084 (0.098)	0.389
Parous women	5216	6147	- 0.041 (0.029)	0.163	0.090 (0.039)	0.019
Parous women + age at 1st birth adjustment	5216	6147	- 0.045 (0.029)	0.121	0.085 (0.038)	0.027
Parous women + age at menopause adjustment	5216	6147	- 0.043 (0.029)	0.139	0.087 (0.038)	0.023
Parous women + age at 1st birth + age at meno- pause adjustments	5216	6147	- 0.047 (0.029)	0.107	0.083 (0.038)	0.031
Nulliparous women—Model D ^d						
All	1059	1229	- 0.197 (0.060)	0.001	— 0.043 (0.075)	0.563
Parous women—Model E ^b						
All	9321	11,024	- 0.036 (0.022)	0.111	0.090 (0.030)	0.002
All + age at 1st birth adjustment	9321	11,024	- 0.038 (0.022)	0.090	0.088 (0.030)	0.003

BMI body mass index, ICMD International Consortium of Mammographic Density, SE standard error

^a A multi-level linear regression model was used to estimate the difference in square-root per cent density and dense area associated with each 10 cm increase in height. Models specified correlations of women (level 1) within population groups (level 2)

^b Models A (all women) and E (parous women): adjusted for age at mammogram³, menopausal status, age at mammogram* menopausal status interaction term, BMI³, use of HRT, mammogram view, calibration, reader, parity, age at menarche

^c Models B (pre-menopausal women) and C (post-menopausal women): adjusted for age at mammogram³, BMI³, use of HRT, mammogram view, calibration, reader, parity, age at menarche

^d Model D (nulliparous women): adjusted for age at mammogram³, menopausal status, age at mammogram* menopausal status interaction term, BMI³, use of HRT, mammogram view, calibration, reader, age at menarche

^e Dense area models: BMI² adjusted for instead of BMI³

well understood. It is well established that adipose tissue deposition is needed for the onset of menarche and increased body adiposity is associated with earlier pubertal development [27]. In this study, we found that the magnitude of the association between age at menarche and PD was doubled without adjustment for BMI, whilst the DA-associated estimates remained similar. This finding highlights the importance of adjustment for BMI whenever estimating associations with PD. The estimates of association stratified by BMI were strongest (and largely driven by) women of average or below mean BMI (<=25 kg/m²).

A recent review postulates that the timing of menarche, in terms of timing of availability of ovarian hormones, can impact breast morphology and, in turn, affect MD [11]. Women who experience a longer pubertal tempo, the time between the development of breast buds and menarche, have been shown to have increased dense area and increased breast cancer risk (independent of the age of onset of puberty) [11]. The review authors concluded that prolonged exposure of breast tissue to ovarian hormones could mediate these associations but further investigations are required.

The positive association of tall stature with breast cancer risk is not completely understood but the primary hypothesized mechanism is through the role of hormones and growth factors, particularly insulinlike growth factor-1 (IGF-1) via its stimulation of bone growth, the promotion of cell proliferation and inhibition of apoptosis [28, 29]. Genetic variants in the IGF pathway and circulating levels of IGF-1 have been associated with increased adult height [2, 30-32]. A Mendelian randomization study using height-associated genetic variants (including variants in the IGF pathway) suggested that adult height was not only a risk factor for breast cancer, but that the association was causal [2]. Circulating IGF-1 has also been independently associated with an increased risk of breast cancer, although with some inconsistent results regarding the effects of menopausal status and tumour subtype [31]. Further, increased levels of IGF-1 have also been associated with increased mammographic density [33, 34]. The increased production of cells in the breast due to increased IGF-1 is thought to lead to increased breast density and eventually to an increased risk of breast cancer [33, 34].

In this study, we found that increased adult height was positively associated with DA. The magnitude of the DA association was also largely independent of adjustment for BMI or age at menarche. Conversely, the association between height and PD is more complex, largely due to increased confounding and the large (expected) heterogeneity between PD and anthropometric measures across 22 international study populations. We found only marginal evidence of a positive association between PD and height but only without adjustment for BMI. Otherwise, PD was negatively associated with height. Taller women tended to have larger breasts (i.e. increased total breast area; data not shown) which may explain why increased height could be associated with lower PD.

The key strengths of this study were the large and ethnically and geographically diverse sample of women, and the comprehensive and harmonized data available across all studies. This also enabled reporting of both population- and group-specific associations, summarized using a meta-analytic approach, as well as overall associations estimated from the pooled individual-level data. The results were largely consistent using both approaches and for both mammographic measures (PD and DA), although the height–PD association depended upon the degree of body size adjustment. This suggests that the results are generalizable to women in populations worldwide.

There are limitations inherent in using existing data that were collected from multiple studies. In this case, this included some evidence of differences in associations with height when stratified by type of measurement (selfreported or measured), introducing a potential source of bias that needs to be taken into account when considering results. Previous studies that have shown the heritability of height vary depending on whether the height data were measured or self-reported [35]. Conversely, other studies have found high correlations between selfreported and measured height and weight in the same individuals, suggesting that the potential for bias may be minimized [36]. Unfortunately, we do not have selfreported and measured height and weight in the same individuals in the ICMD, which would be required to accurately assess the degree of bias. Adjustment for other anthropometric measures such as waist-to-hip ratio and percentage of body fat also warrant future investigation. A further complexity arises given measures of height vary with age. Adult height reflects the body's linear growth, and maximum adult height is achieved in a woman's adolescent or early adult years [37, 38]. However, height measured in later life, especially during post-menopausal ages, includes a degree of shrinkage. A further potential source of bias is therefore introduced depending on the age at which height was measured in each study.

Conclusions

In summary, we have shown in one of the largest international studies to date that later age at menarche and increased adult height are both positively associated with measures of MD. The associations observed for height are in line with previous findings for associations with breast cancer risk, but those for menarche are in the opposite direction. These findings suggest that the association of age at menarche with breast cancer risk is not likely mediated through MD. Whether the well-established positive association of height with breast cancer risk is driven in whole or in part by elevated MD warrants further study. These results suggest a complex relationship between growth and development, MD and breast cancer risk.

Abbreviations

BMI: Body mass index; DA: Dense area; ICMD: International Consortium of Mammographic Density; IGF: Insulin-like growth factor; IGF-1: Insulin-like growth factor-1; MD: Mammographic density; PD: Percent density.

Supplementary Information

The online version contains supplementary material available at https://doi. org/10.1186/s13058-022-01545-9.

Additional file 1. Tables S1 and S2: Supplementary data providing results from sensitivity analyses of pooled models adjusted for a population-specific weight-for-height index instead of BMI

Acknowledgements

The Melbourne Collaborative Cohort Study acknowledges that their cases and their vital status were ascertained through the Victorian Cancer Registry (VCR) and the Australian Institute of Health and Welfare (AIHW), including the National Death Index and the Australian Cancer Database. Isfahan University acknowledges assistance from Dr. Vida Razavi and Dr. Shamila Razavi. Instituto Nacional de Salud Pública acknowledges the Ministry of Education of Mexico and the Institute for Social Security and Services for State Workers' Medical Directorate staff and regional office in Jalisco for technical and administrative support. Where authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of these organizations.

Author Contributions

The study was conceptualized and designed by VM, JSt and ABur and supervised by VM and JSt. Data were curated by GM, BPG, CV, HMi, ML, RLR, AP, MLG, RMT, KB, AK, GU, EL, HMa, SVinn, SMo, SA, RN, SVina, SHT, SMa, BP, AB-D, CN, JSt, JHo, GG, VO, MEA, JSc, CVG, JOPW, RS, MS, JHi, JK, JWL, CD, MH, KSC, CS, AMC, LL, MP, AAF, DS, RK, NB, IdSS and VM. Centralized breast density readings were performed by VM, IdSS and NB, and data harmonization was conducted by ABur. Primary data analyses were performed by SW, with additional analyses and input from VM and ABur. Results were interpreted by SW, JSt, VM, ABur, GM, AP, MLG, KB, BP, MP, NB and IdSS. The manuscript was drafted by SW, JSt, VM and ABur and revised by SW and JSt. All authors reviewed the final manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by the US National Cancer Institute at the National Institutes of Health [R03CA167771]; the International Agency for Research on Cancer; the University of Western Australia [Research Collaboration Award] and the Cancer Council Western Australia [Capacity Building and Collaboration Grant]. Original studies were supported, according to country by: *Australia* VicHealth; Cancer Council Victoria; Australian National Health and Medical Research Council [209057, 251,553 and 504711]; Australian National Breast Cancer Foundation [to JSt]; *Canada* the National Cancer Institute of Canada [to NFB]; *Chile* Fondecyt [11100238 to MLG, 1120326, 1130277, 3130532]; World Cancer Research Fund [2010/245]; Ellison Medical Foundation Grant [to AP]; *Iran* Isfahan University of Medical Sciences; *Israel* The Israel Cancer Association; *Republic of Korea* Asan Medical Center [2010-0811]; *Malaysia* Sime Darby LPGA Tournament; Ministry of Education University Malaya [Research Grant UMRG RP0468-15HTM]; *Mexico* National Council of Science and Technology (Mexico); the

American Institute for Cancer Research [10A035]; Netherlands EPIC-NL-Europe against Cancer Programme of the European Commission (SANCO); Dutch Ministry of Health; Dutch Cancer Society; ZonMW the Netherlands Organisation for Health Research and Development; World Cancer Research Fund (WCRF); Poland Polish-Norwegian Research Programme [PNRF-243-AI-1/07]; Singapore National Medical Research Council [Clinician Scientist Award]; National University Cancer Institute Singapore (NCIS) Centre grant programme from National Medical Research Council; South Africa Pink Drive; Spain Spain's Health Research Fund (Fondo de Investigacion Santiaria) [PI060386 and PS09/0790]; Spanish Federation of Breast Cancer Patients (FECMA) [EPY1169-10]; Turkey-Roche Mustahzarlari San. A.S., Istanbul, Turkey; UK UK Engineering and Physical Sciences Research Council [EP/K020439/1 to JHi]; Breast Cancer Campaign [2007MayPR23], Cancer Research UK [G186/11 and C405/A14565]; Da Costa Foundation UK; USA National Cancer Institute [R01CA85265, R37 CA54281, R01 CA97396, P50 CA116201, R01 CA177150 and R01 CA140286]; Cancer Center Support Grant [CA15083; CA131332, CA124865, UM1 CA186107 and UM1 CA176726]; the Susan G. Komen Foundation.

Availability of data and materials

ICMD data cannot be deposited publicly as these data originate from 27 research institutions across 22 countries with different legal and ethical frameworks. Researchers seeking the analysis data set for this work are able to apply to the Environment and Lifestyle Epidemiology Branch at the International Agency for Research on Cancer for access (email: env@iarc.fr).

Declarations

Ethics approval and consent to participate

Ethics approvals for ICMD were obtained from the International Agency for Research on Cancer (IEC 12 \pm 34). Each individual study obtained informed consent to participate from women included in the study and had received local ethical approval at the time of the original conduct of the study and again to contribute to the consortium.

Consent for publication

Not applicable.

Competing interests

ML declares a non-restricted investigator-initiated grant from AstraZeneca and minor support from Swiss Re.

Author details

School of Population and Global Health, The University of Western Australia, Perth, Australia.²Environment and Lifestyle Epidemiology Branch, International Agency for Research on Cancer, 150 Cours Albert Thomas, 69372 Lyon Cedex 08, France. ³Translation Health Sciences, University of Bristol, Bristol, UK. ⁴Population Health Sciences, Weill Cornell Medical College, Cornell University, New York, USA. ⁵Institute of Nutrition and Food Technology, University of Chile, Santiago, Chile. ⁶Cancer and Environmental Epidemiology Unit, Instituto de Salud Carlos III, Madrid, Spain. ⁷Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain. ⁸Princess Margaret Cancer Centre, Toronto, ON, Canada. 9Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK. ¹⁰University of Hawaii Cancer Center, Honolulu, HI, USA. ¹¹Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA. ¹²Saw Swee Hock School of Public Health, National University of Singapore, Singapore City, Singapore.¹³Instituto Nacional de Salud Pública, Cuernavaca, Mexico. ¹⁴Slone Epidemiology Center at, Boston University, Boston, MA, USA. ¹⁵Division of Breast Surgery, Faculty of Medicine, University of Hong Kong, Pok Fu Lam, Hong Kong, China. ¹⁶Department of Surgery and Cancer Genetics Center, Hong Kong Sanatorium and Hospital, Pok Fu Lam, Hong Kong, China. ¹⁷Hong Kong Hereditary Breast Cancer Family Registry, Pok Fu Lam, Hong Kong, China. ¹⁸Cancer Registry of Norway, Oslo, Norway. ¹⁹Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway. ²⁰Department of Preventive Medicine, University of Southern California, Los Angeles, CA, USA. ²¹Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, USA. ²²Department of Population Sciences, City of Hope National Medical Center, Duarte, CA, USA. ²³Division of Cancer Research, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland, UK.²⁴Wolfson Institute of Preventive

Medicine, Queen Mary University of London, London, UK. ²⁵Department of Imaging, Royal Marsden NHS Foundation Trust, London, UK.²⁶Aga Khan University Hospital, Nairobi, Kenya.²⁷Breast Cancer Research Group, University Malaya Medical Centre, University Malaya, Kuala Lumpur, Malaysia.²⁸Cancer Research Malaysia, Subang Jaya, Malaysia.²⁹Department of Environmental Epidemiology, Nofer Institute of Occupational Medicine, Łódź, Poland. ³⁰Department of Physiology, Pathophysiology and Clinical Immunology, Medical University of Lodz., Łódź, Poland. ³¹Department of Epidemiology and Preventive Medicine, Graduate School of Medicine, Gifu University, Gifu, Japan. ³²Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia.³³Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, VIC, Australia. ³⁴Faculty of Medicine, Istanbul University, Istanbul, Turkey ³⁵Department of Radiology, School of Medicine, Marmara University, Istanbul, Turkey. ³⁶ Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands. ³⁷Radiology Department, George Washington University Hospital, Washington, DC, USA. ³⁸Radiology Department, Isfahan University of Medical Sciences, Isfahan, Iran. ³⁹Centre for Medical Image Computing, University College London, London, UK.⁴⁰Asan Medical Center, Seoul, Republic of Korea. ⁴¹Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. ⁴²Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore City, Singapore. ⁴³NUS Graduate School for Integrative Sciences and Engineering, National University of Singapore, Singapore, Singapore.⁴⁴Ontario Breast Screening Program, Cancer Care Ontario, Toronto, ON, Canada.⁴⁵National Cancer Control Center, Lady Davis Carmel Medical Center, Faculty of Medicine, Technion-Israel Institute Technology, Haifa, Israel. ⁴⁶Woman Imaging Unit, Radiodiagnosis Department, Kasr El Aini, Cairo University Hospitals, Cairo, Egypt.

Received: 7 February 2022 Accepted: 29 June 2022 Published online: 14 July 2022

References

- Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol. 2012;13(11):1141–51.
- Zhang B, Shu X-O, Delahanty RJ, Zeng C, Michailidou K, Bolla MK, et al. Height and breast cancer risk: evidence from prospective studies and mendelian randomization. J Natl Cancer Inst. 2015;107(11):219.
- Boyd NF, Stone J, Martin LJ, Jong R, Fishell E, Yaffe M, et al. The association of breast mitogens with mammographic densities. Br J Cancer. 2002;87(8):876–82.
- McCormack VA, dos Santos SI. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomark Prev. 2006;15(6):1159.
- Bond-Smith D, Stone J. Methodological challenges and updated findings from a meta-analysis of the association between mammographic density and breast cancer. Cancer Epidemiol Biomark Prev. 2019;28(1):22.
- Huo CW, Chew GL, Britt KL, Ingman WV, Henderson MA, Hopper JL, et al. Mammographic density—a review on the current understanding of its association with breast cancer. Breast Cancer Res Treat. 2014;144(3):479–502.
- Boyd NF, Martin LJ, Sun L, Guo H, Chiarelli A, Hislop G, et al. Body size, mammographic density, and breast cancer risk. Cancer Epidemiol Biomark Prev. 2006;15(11):2086.
- Boyd NF, Lockwood GA, Martin LJ, Knight JA, Byng JW, Yaffe MJ, et al. Mammographic densities and breast cancer risk. Breast Dis. 1998;10:113–26.
- Andersen ZJ, Baker JL, Bihrmann K, Vejborg I, Sørensen TIA, Lynge E. Birth weight, childhood body mass index, and height in relation to mammographic density and breast cancer: a register-based cohort study. Breast Cancer Res. 2014;16(1):R4.
- Harris HR, Tamimi RM, Willett WC, Hankinson SE, Michels KB. Body size across the life course, mammographic density, and risk of breast cancer. Am J Epidemiol. 2011;174(8):909–18.

- Ghadge AG, Dasari P, Stone J, Thompson EW, Robker RL, Ingman WV. Pubertal mammary gland development is a key determinant of adult mammographic density. Semin Cell Dev Biol. 2021;114:143–58.
- Rice MS, Bertrand KA, VanderWeele TJ, Rosner BA, Liao X, Adami H-O, et al. Mammographic density and breast cancer risk: a mediation analysis. Breast Cancer Res. 2016;18(1):94.
- Heng D, Gao F, Jong R, Fishell E, Yaffe M, Martin L, et al. Risk factors for breast cancer associated with mammographic features in Singaporean Chinese women. Cancer Epidemiol Biomark Prev. 2004;13(11):1751.
- Boyd NF, Lockwood GA, Byng JW, Little LE, Yaffe MJ, Tritchler DL. The relationship of anthropometric measures to radiological features of the breast in premenopausal women. Br J Cancer. 1998;78(9):1233–8.
- Neuhouser ML, Aragaki AK, Prentice RL, Manson JE, Chlebowski R, Carty CL, et al. Overweight, obesity, and postmenopausal invasive breast cancer risk: a secondary analysis of the women's health initiative randomized clinical trials. JAMA Oncol. 2015;1(5):611–21.
- Jeffreys M, Warren R, Gunnell D, McCarron P, Smith GD. Life course breast cancer risk factors and adult breast density (United Kingdom). Cancer Causes Control. 2004;15(9):947–55.
- Onland-Moret NC, Peeters PHM, van Gils CH, Clavel-Chapelon F, Key T, Tjønneland A, et al. Age at menarche in relation to adult height: the EPIC study. Am J Epidemiol. 2005;162(7):623–32.
- Okasha M, Gunnell D, Holly J, Davey Smith G. Childhood growth and adult cancer. Best Prac Res Clin Endocrinol Metab. 2002;16(2):225–41.
- McCormack VA, Burton A, dos-Santos-Silva I, Hipwell JH, Dickens C, Salem D, et al. International Consortium on Mammographic Density: Methodology and population diversity captured across 22 countries. Cancer Epidemiol. 2016;40:141–51.
- Burton A, Maskarinec G, Perez-Gomez B, Vachon C, Miao H, Lajous M, et al. Mammographic density and ageing: a collaborative pooled analysis of cross-sectional data from 22 countries worldwide. PLOS Med. 2017;14(6):e1002335.
- 21. Byng JW, Boyd NF, Fishell E, Jong RA, Yaffe MJ. The quantitative analysis of mammographic densities. Phys Med Biol. 1994;39(10):1629–38.
- 22. Burton A, Byrnes G, Stone J, Tamimi RM, Heine J, Vachon C, et al. Mammographic density assessed on paired raw and processed digital images and on paired screen-film and digital images across three mammography systems. Breast Cancer Res. 2016;18(1):130.
- 23. Diverse Populations Collaborative Group. Weight-height relationships and body mass index: some observations from the diverse populations collaboration. Am J Phys Anthropol. 2005;128(1):220–9.
- Sperrin M, Marshall AD, Higgins V, Renehan AG, Buchan IE. Body mass index relates weight to height differently in women and older adults: serial cross-sectional surveys in England (1992–2011). J Public Health. 2016;38(3):607–13.
- Schoemaker MJ, Jones ME, Allen S, Hoare J, Ashworth A, Dowsett M, et al. Childhood body size and pubertal timing in relation to adult mammographic density phenotype. Breast Cancer Res. 2017;19(1):13.
- Ma H, Bernstein L, Pike MC, Ursin G. Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Res. 2006;8(4):R43.
- Li W, Liu Q, Deng X, Chen Y, Liu S, Story M. Association between obesity and puberty timing: a systematic review and meta-analysis. Int J Environ Res Public Health. 2017;14(10):1266.
- Guntur AR, Rosen CJ. IGF-1 regulation of key signaling pathways in bone. Bonekey Rep. 2013;2:437–437.
- Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer. 2004;4(7):505–18.
- Biro FM, Huang B, Wasserman H, Gordon CM, Pinney SM. Pubertal growth, IGF-1, and windows of susceptibility: puberty and future breast cancer risk. J Adolesc Health. 2021;68(3):517–22.
- Endogenous Hormones and Breast Cancer Collaborative Group, Key TJ, Appleby PN, Reeves GK, Roddam AW. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol. 2010;11(6):530–42.
- He M, Xu M, Zhang B, Liang J, Chen P, Lee J-Y, et al. Meta-analysis of genome-wide association studies of adult height in East Asians identifies 17 novel loci. Hum Mol Genet. 2015;24(6):1791–800.

- Diorio C, Pollak M, Byrne C, Mâsse B, Hébert-Croteau N, Yaffe M, et al. Insulin-like growth factor-I, IGF-binding protein-3, and mammographic breast density. Cancer Epidemiol Biomark Prev. 2005;14(5):1065–73.
- Dos Santos SI, Johnson N, De Stavola B, Torres-Mejía G, Fletcher O, Allen DS, et al. The insulin-like growth factor system and mammographic features in premenopausal and postmenopausal women. Cancer Epidemiol Biomark Prev. 2006;15(3):449–55.
- Macgregor S, Cornes BK, Martin NG, Visscher PM. Bias, precision and heritability of self-reported and clinically measured height in Australian twins. Hum Genet. 2006;120(4):571–80.
- Peplonska B, Bukowska A, Sobala W. Association of rotating night shift work with BMI and abdominal obesity among nurses and midwives. PLoS ONE. 2015;10(7):e0133761.
- 37. Li Cl, Littman AJ, White E. Relationship between Age maximum height is attained, age at menarche, and age at first full-term birth and Breast Cancer Risk. Cancer Epidemiol Biomark Prev. 2007;16(10):2144–9.
- Baer HJ, Rich-Edwards JW, Colditz GA, Hunter DJ, Willett WC, Michels KB. Adult height, age at attained height, and incidence of breast cancer in premenopausal women. Int J Cancer. 2006;119(9):2231–5.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

